Medac Pharm / medac GmbH
↗Wedel, Germany (near Hamburg)
Medac GmbH is a privately-owned German pharmaceutical company founded in 1970, headquartered in Wedel near Hamburg with additional operations in Tornesch, Germany. With over 2,000 employees worldwide, the company specializes in improving established pharmaceutical products and diagnostics while developing new therapies in four key therapeutic areas: rheumatology, urology, hematology, and oncology. Medac is recognized as a global innovator in therapeutic agents for oncological, urological, and autoimmune diseases, distributing pharmaceuticals and diagnostics to 95 countries worldwide. The company operates advanced manufacturing facilities in Germany (Wedel and Dessau) and Czech Republic (Brno), maintaining strict quality standards for all products.
CLASSIFICATION
Company Type:Pharma
Therapeutic Areas:
Industry:Pharmaceuticals
Sub-Industry:Specialty Pharma | Oncology | Rheumatology | Hematology | Urology
SIZE & FINANCIALS
Employees:1001-5000
Founded:1970
Ownership:private
Status:operating
FUNDING
Investors:Medexus Pharmaceuticals (acquired Medac Pharma Inc subsidiary in 2018 for $50M)
PIPELINE
Stage:Commercial|Phase 2|Preclinical
Lead Drug Stage:Commercial
Modalities:Small molecule, Biosimilars, Cell therapies, Monoclonal antibodies, Oncology compounds, Diagnostic agents
Trial Phases:Phase 2: 1
FDA Approvals:1
CORPORATE STRUCTURE
Acquired By:Medexus Pharmaceuticals (partial - Medac Pharma subsidiary acquired; parent company Medac GmbH remains independent) (2018-10-16)
Subsidiaries:Medac Pharma Inc. (USA - acquired by Medexus Pharmaceuticals 2018), oncotec GmbH (Dessau, Germany - 50% owned), oncomed a.s. (Brno, Czech Republic - 50% owned), Medac UK Ltd, Medac France, Medac Italy, Medac Japan
Key Partnerships:Glycostem Therapeutics: Exclusive license to commercialize oNKord (GTA002) in EU, UK and Europe for AML and MM, UroGen Pharma: License and supply agreement for next-generation mitomycin formulation (UGN-103), Fresenius Kabi: Medac sales representatives commercialize IDACIO (adalimumab biosimilar) from June 2020, Medexus Pharmaceuticals: Agreement for Treosulfan (conditioning agent for hematopoietic stem cell transplantation) in USA
COMPETITION
Position:Niche Player
Competitors:Biogen, Grifols, UCB, Regeneron Pharmaceuticals, GSK, Genetic, Lubrizol Particle Sciences, Nevian Lifescience +2 more
LEADERSHIP
Key Executives:
Frank Lucaßen - Chief Executive Officer (CEO)
Frank Generotzky - Chief Operating Officer (COO)
Heiner Will - Chief Business Development and Science Officer (former)
Scientific Founders:Wilfried Mohr, Claus-Olaf Welding, Dr. Werner Mai, Ernst Voss
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Medac Pharm / medac GmbH. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.